

Published 12/19/2008: Correction to Title and Comment Period.

Dated: December 29, 2008.

**Robert W. Hargrove,**

*Director, NEPA Compliance Division, Office of Federal Activities.*

[FR Doc. E8-31218 Filed 12-31-08; 8:45 am]

**BILLING CODE 6560-50-P**

*Irvine, California;* to acquire up to 18 percent of Heritage Bank, National Association, New York, New York.

Board of Governors of the Federal Reserve System, December 29, 2008.

**Jennifer J. Johnson,**

*Secretary of the Board.*

[FR Doc. E8-31199 Filed 12-31-08; 8:45 am]

**BILLING CODE 6210-01-S**

Dated: December 29, 2008.

**Russell H. Pentz,**

*Assistant Deputy Associate Administrator, Office of Travel, Transportation, and Asset Management.*

[FR Doc. E8-31231 Filed 12-31-08; 8:45 am]

**BILLING CODE 6820-14-P**

## FEDERAL RESERVE SYSTEM

### Formations of, Acquisitions by, and Mergers of Bank Holding Companies

The companies listed in this notice have applied to the Board for approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C. 1841 *et seq.*) (BHC Act), Regulation Y (12 CFR Part 225), and all other applicable statutes and regulations to become a bank holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a bank or bank holding company and all of the banks and nonbanking companies owned by the bank holding company, including the companies listed below.

The applications listed below, as well as other related filings required by the Board, are available for immediate inspection at the Federal Reserve Bank indicated. The applications also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the acquisition of a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 4 of the BHC Act (12 U.S.C. 1843). Unless otherwise noted, nonbanking activities will be conducted throughout the United States. Additional information on all bank holding companies may be obtained from the National Information Center website at [www.ffiec.gov/nic/](http://www.ffiec.gov/nic/).

Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than January 26, 2009.

**A. Federal Reserve Bank of San Francisco** (Tracy Basinger, Director, Regional and Community Bank Group) 101 Market Street, San Francisco, California 94105-1579:

1. *Carpenter Fund Manager GP, LLC, Carpenter Fund Management, LLC, Carpenter Community Bancfund, L.P., Carpenter Community Bancfund-A, L.P., Carpenter Community Bancfund-CA, L.P., CCFW, Inc., and SCJ, Inc., all of*

## GENERAL SERVICES ADMINISTRATION

### Federal Travel Regulation (FTR); Relocation Allowances; Notice of GSA Bulletin FTR 09-03

**AGENCY:** Office of Governmentwide Policy, General Services Administration (GSA).

**ACTION:** Notice of a bulletin.

**SUMMARY:** On December 11, 2007, the General Services Administration (GSA) published FTR Amendment 2007-06 in the *Federal Register* (72 FR 70234) specifying that the Internal Revenue Service (IRS) Standard Mileage Rate for moving purposes would be the rate at which agencies will reimburse an employee for using a privately-owned vehicle for relocation on a worldwide basis. The amendment indicated that the change to the IRS Standard Mileage Rate for moving purposes applied to relocations on and after September 25, 2007, and that GSA would publish a bulletin announcing any changes to that rate made by the IRS thereafter. On November 24, 2008, the IRS announced that as of January 1, 2009, the relocation mileage rate would decrease to \$0.24 per mile for the 12 month period ending on December 31, 2009. Thus, the reimbursement rate for relocation will also be \$0.24 for the same period. GSA Bulletin FTR 09-03 may be found at <http://www.gsa.gov/federaltravelregulation>.

**DATES:** The bulletin announced in this notice became effective December 12, 2008, and applies to relocations performed on or after January 1, 2009 until December 31, 2009.

**FOR FURTHER INFORMATION CONTACT:** Mr. Ed Davis, Office of Governmentwide Policy (M), Office of Travel, Transportation, and Asset Management (MT), General Services Administration at (202) 208-7638 or via e-mail at [ed.davis@gsa.gov](mailto:ed.davis@gsa.gov). Please cite FTR Bulletin 09-03.

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Solicitation of Written Comments on Draft Centers for Disease Control and Prevention's Immunization Safety Office Scientific Agenda

**AGENCY:** Department of Health and Human Services, Office of the Secretary.  
**ACTION:** Notice.

**SUMMARY:** The National Vaccine Program Office (NVPO) is soliciting public comment on the Centers for Disease Control and Prevention's Immunization Safety Office (ISO) draft Scientific Agenda related to scientific research questions in vaccine safety.

**DATES:** Comments on the draft ISO Scientific Agenda should be received no later than 5 p.m. on February 2, 2009.

**ADDRESSES:** Electronic responses are preferred and may be addressed to [vaccinsafetyRFI@hhs.gov](mailto:vaccinsafetyRFI@hhs.gov). Written responses should be addressed to National Vaccine Program Office, U.S. Department of Health and Human Services, 200 Independence Avenue, SW., Room 443-H, Washington, DC 20201, Attention: Vaccine Safety RFI.

**FOR FURTHER INFORMATION CONTACT:** Ms. Kirsten Vannice, National Vaccine Program Office, Department of Health and Human Services, Hubert H. Humphrey Building, 200 Independence Avenue, SW., Room 443-H, Washington, DC 20201; telephone (202) 690-5566; fax 202-260-1165; e-mail [vaccinesafetyRFI@hhs.gov](mailto:vaccinesafetyRFI@hhs.gov).

#### SUPPLEMENTARY INFORMATION:

##### I. Background

Ensuring the optimal safety of vaccines and immunizations is important to everyone. NVPO is located within the Office of Public Health and Science within the Office of the Secretary, Department of Health and Human Services (HHS), and has responsibility for coordinating and ensuring collaboration among the many Federal agencies involved in vaccine and immunization activities. NVAC is a statutory Federal advisory committee that provides advice and makes recommendations to the Director of the National Vaccine Program on matters related to the program.

Vaccine safety research is done from the time vaccine development begins through when it is licensed and used routinely. Within HHS, vaccine and vaccine safety research during the development process is supported primarily by the National Institutes of Health. The Food and Drug Administration then carefully reviews safety and effectiveness information in deciding whether a vaccine should be licensed. After licensure, when a vaccine is used in children, adolescents or adults, its safety is monitored and further scientific studies are done to assure that the vaccine is safe, to evaluate potential safety problems, or to identify ways that the vaccine can be used more safely.

The Center for Disease Control and Prevention's (CDC) Immunization Safety Office (ISO) has significant responsibility for monitoring and studying the safety of vaccines after they are licensed and used in the United States (<http://www.cdc.gov/vaccinesafety>). ISO has drafted a scientific agenda that identifies vaccine safety issues to consider for scientific study over the next five years, in addition to any new questions that may arise. Since not all questions and issues can be addressed at once, setting priorities is important. The draft ISO Scientific Agenda can be found at: [http://www.cdc.gov/vaccinesafety/00\\_pdf/draft\\_agenda\\_recommendations\\_080404.pdf](http://www.cdc.gov/vaccinesafety/00_pdf/draft_agenda_recommendations_080404.pdf) and the addendum at [http://www.cdc.gov/vaccinesafety/00\\_pdf/draft\\_recommendations\\_add\\_080410.pdf](http://www.cdc.gov/vaccinesafety/00_pdf/draft_recommendations_add_080410.pdf).

ISO has requested a review of the draft Scientific Agenda by the National Vaccine Advisory Committee (NVAC).

The NVAC review of the draft ISO Scientific Agenda will include providing recommendations on the agenda contents and on priorities for scientific research either done or funded by ISO. Public and stakeholder input will be important to the development of the NVAC recommendations, along with the expertise of the NVAC and NVAC Vaccine Safety Working Group members. Public and stakeholder input is being requested by written comment in response to this RFI; at community meetings taking place in Ashland, OR, Birmingham, AL, and Indianapolis, IN; at a meeting of stakeholders; and at a meeting of the NVAC Vaccine Safety Working Group (for more information, see <http://www.hhs.gov/nvpo/nvac/PublicEngagement.html>).

Through this RFI, HHS is seeking comments from everyone, including stakeholders and the broad public. Comments received will be available for

public viewing and will be presented in an open meeting on February 4, 2009, to the NVAC Vaccine Safety Working Group.

## II. Information Request

NVPO, on behalf of the NVAC Vaccine Safety Working Group requests input in three broad areas: (1) Concerns about vaccines and immunization safety, (2) comments on what values, considerations, or factors are most important to consider in prioritizing scientific research, and (3) specific comments on the draft ISO Scientific Agenda. Responders may address one or all of the topics below.

(1) *Concerns about vaccines and immunization safety:* What are your primary concerns about the safety of vaccines and immunization? Why are those concerns most important to you? If interested, please share any personal experience that may further explain your concerns and their importance. [Provide up to 3 pages for an answer to this question]

(2) *Comments on what values or factors are most important to consider in prioritizing scientific research:* What values, considerations, or factors are most important to you in deciding what vaccine and immunization safety research should be conducted first? Why are these values, considerations, and factors most important to you? Examples of values or factors that you may consider include, but are not limited to, the frequency, severity, or duration of an event; the age, number of people, or vulnerability of persons exposed to a vaccine; the amount of scientific or public concern; and whether or not a vaccine is required for child-care or school entry or as a condition for employment. [Provide up to 3 pages for an answer to this question]

(3) *Specific comments on the ISO draft scientific agenda:* The draft CDC ISO Scientific Agenda can be viewed and downloaded from the CDC Web site (internet address is provided in the Background section, above).

a. Please provide any general comments on the draft ISO Scientific Agenda.

b. The following questions relate to the 30 items identified as potential 5-year research needs (see page 27 of draft ISO Scientific Agenda for a condensed list):

i. What scientific issues should be included in the draft ISO Scientific Agenda that are not there now, or what issues that are currently included should be removed? Why should these issues be added or deleted?

ii. What issues in the draft ISO Scientific Agenda are most important to you and should be made a priority to study and what issues are least important to you? Why are they the highest or lowest priorities?

[Provide up to 3 pages for an answer to this question]

## III. Potential Responders

HHS invites input from a broad range of individuals and organizations that have interests in vaccines and vaccine safety. Some examples of these organizations include but are not limited to the following:

- General public;
- Advocacy groups and public interest organizations;
- State and local governments;
- State and local public health departments;
- Vaccine manufacturing industry, distributors and other businesses;
- Health care professional societies and organizations.

When responding, please self-identify with any of the above or other categories (include all that apply) and your name. Anonymous submissions will not have their comments posted.

The submission of written materials in response to the RFI should not exceed 9 pages (3 pages for each of the three broad topics), not including appendices and supplemental documents. Responders may submit other forms of electronic materials to demonstrate or exhibit concepts of their written responses. Any information you submit will be made public. Consequently, do not send proprietary, commercial, financial, business confidential, trade secret, or personal information that you do not wish to be made public.

Public Access: Responses to this RFI will be available to the public on the NVAC Web site at <http://www.hhs.gov/nvpo/nvac/PublicEngagement/RFIResponses.html>. You may access public comments received from this RFI by going to the above Web site.

Dated: December 22, 2008.

**Raymond A. Strikas,**

*Acting Director, National Vaccine Program Office, U.S. Department of Health and Human Services.*

[FR Doc. E8-31196 Filed 12-31-08; 8:45 am]

BILLING CODE 4150-44-P